Alderley Park, Block 24
Suite 24G13 Congleton Road
Nether Alderley SK10 4TG
United Kingdom
44 1625 315 090
https://evgen.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Huw Jones BSc, Ph.D. | CEO & Executive Director | 304.73k | N/A | 1959 |
Mr. Toni Haenninen | CFO & Director | N/A | N/A | 1977 |
Dr. Helen Kuhlman | Chief Business Officer | N/A | N/A | N/A |
Dr. Glen Clack FFPM, M.D. | Chief Medical Officer | N/A | N/A | N/A |
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.